Press releases
- Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
- Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
- Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
- Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
- Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
More ▼
Key statistics
On Thursday, Alpine Immune Sciences Inc (34LA:DEU) closed at 60.00, -3.23% below its 52-week high of 62.00, set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 60.50 |
---|---|
High | 61.00 |
Low | 59.00 |
Bid | 59.00 |
Offer | 61.50 |
Previous close | 59.50 |
Average volume | 254.40 |
---|---|
Shares outstanding | 65.55m |
Free float | 62.50m |
P/E (TTM) | -- |
Market cap | 4.23bn USD |
EPS (TTM) | -0.6827 USD |
Data delayed at least 15 minutes, as of May 02 2024.
More ▼